As psychedelics move toward potential FDA approval, Oregon’s psilocybin service centers offer early lessons in patient-centered care. This article examines real-world practices in preparation, dosing, facilitation, and integration—and what they may reveal about future clinical use.
Judy Lytle
Executive Director of Evidence Development Study Solutions
Immune checkpoint inhibitors deliver transformative outcomes, yet real‑world durability is often limited by primary and acquired resistance. This article explores the biological foundations of ICI resistance and outlines how integrating these insights into HEOR models can improve value assessment and real‑world decision‑making.
As AI becomes embedded across pharmacovigilance, the skills required of safety scientists are rapidly evolving. This article examines the shifting balance between human expertise and AI-enabled tools, outlining the competencies, training pathways, and cultural changes needed to prepare tomorrow’s hybrid PV workforce.
Instability is woven into our industry’s DNA. We operate daily in a high-stakes, high-risk environment where financial pressures, regulatory changes, and patient lives hang in the balance. The CRO selection process reflects this tension, few other sectors require competitors to both challenge and collaborate with one another, often for the same client. Our ecosystem is […]
In this expert interview, UBC’s Tom Coles and Peter Psarologos dive into the essential role of the QPPV in EU pharmacovigilance. From legal requirements to strategic value across the product lifecycle, discover how UBC helps clients stay compliant, inspection-ready, and focused on patient safety.
Recently, Aaron Berger, SVP of Evidence Development Solutions, had a chance to sit down and talk with Joel White of Marketcap consultants, to discuss the state of life science trends and the next wave of real world evidence generation. Joel has long been an important voice in the life sciences space, always with his finger […]
Explore how UBC is leading the transformation of clinical research through decentralized, direct-to-patient study designs. In this interview, Aaron Berger shares insights on improving patient access, data quality, and trial efficiency through UBC’s Evidence Development Solutions.
As Real World Evidence (RWE) continues to shape regulatory decision-making, the FDA and Duke Margolis Institute convened a public meeting to share successes, challenges, and lessons learned in RWE submissions. With over 4,000 attendees, the event spotlighted case studies, data feasibility, and the evolving role of RWE in labeling, post-marketing commitments, and registrational trials. Learn how sponsors are partnering with regulators to modernize study design and advance global RWE standards.
Judy Lytle
Executive Director, Evidence Development Study Solutions
Pharmacies are essential to REMS—but manual processes and fragmented systems create risk and inefficiency. UBC’s RAPID API offers a secure, standards-based integration that streamlines REMS activities directly within pharmacy workflows. Learn how RAPID reduces burden, improves data quality, and elevates patient safety across the REMS ecosystem.
Designing a database study can be challenging with the proliferation of RWD availability and source diversity. Learn how to ensure that database feasibility assessments successfully identify the most relevant data sources appropriate for the evaluation of study objectives.
Patient engagement plays a central role in medication adherence, persistence, and retention. Explore how digital tools, including EHRs, electronic healthcare technology, and digital assistants, can contribute meaningfully to patient engagement.
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.